EP1917034A4 - Conjugue cytotoxique specifique de l'antigene ca6 et methodes d'utilisation de ce dernier - Google Patents
Conjugue cytotoxique specifique de l'antigene ca6 et methodes d'utilisation de ce dernierInfo
- Publication number
- EP1917034A4 EP1917034A4 EP05788869A EP05788869A EP1917034A4 EP 1917034 A4 EP1917034 A4 EP 1917034A4 EP 05788869 A EP05788869 A EP 05788869A EP 05788869 A EP05788869 A EP 05788869A EP 1917034 A4 EP1917034 A4 EP 1917034A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- antigen
- methods
- same
- specific cytotoxic
- cytotoxic conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 231100000433 cytotoxic Toxicity 0.000 title 1
- 230000001472 cytotoxic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2005/030115 WO2007024222A1 (fr) | 2005-08-22 | 2005-08-22 | Conjugue cytotoxique specifique de l'antigene ca6 et methodes d'utilisation de ce dernier |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1917034A1 EP1917034A1 (fr) | 2008-05-07 |
EP1917034A4 true EP1917034A4 (fr) | 2009-04-29 |
Family
ID=37771883
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05788869A Withdrawn EP1917034A4 (fr) | 2005-08-22 | 2005-08-22 | Conjugue cytotoxique specifique de l'antigene ca6 et methodes d'utilisation de ce dernier |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1917034A4 (fr) |
JP (1) | JP2009504193A (fr) |
CN (1) | CN101242855A (fr) |
AU (1) | AU2005335743A1 (fr) |
BR (1) | BRPI0520509A2 (fr) |
CA (1) | CA2615761A1 (fr) |
EA (1) | EA020130B9 (fr) |
EC (1) | ECSP088241A (fr) |
HK (1) | HK1211965A1 (fr) |
IL (2) | IL189628A0 (fr) |
MX (1) | MX2008002607A (fr) |
NO (1) | NO20080893L (fr) |
WO (1) | WO2007024222A1 (fr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
JP6605331B2 (ja) * | 2013-02-05 | 2019-11-13 | サノフイ | 抗体−薬物複合体治療での使用のための免疫造影剤 |
KR20150113196A (ko) * | 2013-02-05 | 2015-10-07 | 사노피 | 항체-약물 컨쥬게이트 치료법에 사용하기 위한 면역 영상제 |
JP2016515093A (ja) * | 2013-02-05 | 2016-05-26 | サノフイ | 抗体−薬物コンジュゲート療法とともに使用するための免疫イメージング剤 |
US9989524B2 (en) | 2013-02-05 | 2018-06-05 | Sanofi | Immuno imaging agent for use with antibody-drug conjugate therapy |
KR20160035600A (ko) * | 2013-08-02 | 2016-03-31 | 사노피 | 고형 종양의 치료를 위한 항-muc1 메이탄시노이드 면역접합체 항체의 용도 |
CN113842468A (zh) | 2014-09-02 | 2021-12-28 | 伊缪诺金公司 | 用于配制抗体药物缀合物组合物的方法 |
SG11201701455SA (en) | 2014-09-03 | 2017-03-30 | Immunogen Inc | Cytotoxic benzodiazepine derivatives |
WO2016036804A1 (fr) | 2014-09-03 | 2016-03-10 | Immunogen, Inc. | Dérivés de benzodiazépine cytotoxique |
JP2019501139A (ja) | 2015-11-25 | 2019-01-17 | イミュノジェン・インコーポレーテッド | 医薬製剤及びその使用 |
US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
AU2018229277A1 (en) | 2017-02-28 | 2019-10-10 | Immunogen, Inc. | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof |
US20180346488A1 (en) | 2017-04-20 | 2018-12-06 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives and conjugates thereof |
US11932650B2 (en) | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
EP3732178A1 (fr) | 2017-12-28 | 2020-11-04 | ImmunoGen, Inc. | Dérivés de benzodiazépine |
WO2020247054A1 (fr) | 2019-06-05 | 2020-12-10 | Massachusetts Institute Of Technology | Composés, conjugués et compositions d'épipolythiodicétopipérazines et de polythiodicétopipérazines et leurs utilisations |
WO2022182415A1 (fr) | 2021-02-24 | 2022-09-01 | Massachusetts Institute Of Technology | Dérivés d'himastatine, leurs procédés de préparation et leurs utilisations |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040241174A1 (en) * | 2003-05-14 | 2004-12-02 | Immunogen, Inc. | Drug conjugate composition |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6596503B1 (en) * | 2000-08-18 | 2003-07-22 | East Carolina University | Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof |
ATE496944T1 (de) * | 2003-07-21 | 2011-02-15 | Immunogen Inc | Ca6-antigenspezifisches zytotoxisches konjugat und verfahren zu dessen anwendung |
-
2005
- 2005-08-22 CN CNA200580051368XA patent/CN101242855A/zh active Pending
- 2005-08-22 CA CA002615761A patent/CA2615761A1/fr not_active Abandoned
- 2005-08-22 BR BRPI0520509-3A patent/BRPI0520509A2/pt not_active Application Discontinuation
- 2005-08-22 WO PCT/US2005/030115 patent/WO2007024222A1/fr active Application Filing
- 2005-08-22 JP JP2008527882A patent/JP2009504193A/ja not_active Withdrawn
- 2005-08-22 MX MX2008002607A patent/MX2008002607A/es not_active Application Discontinuation
- 2005-08-22 EA EA200800642A patent/EA020130B9/ru not_active IP Right Cessation
- 2005-08-22 AU AU2005335743A patent/AU2005335743A1/en not_active Abandoned
- 2005-08-22 EP EP05788869A patent/EP1917034A4/fr not_active Withdrawn
-
2008
- 2008-02-20 NO NO20080893A patent/NO20080893L/no not_active Application Discontinuation
- 2008-02-20 IL IL189628A patent/IL189628A0/en unknown
- 2008-03-05 EC EC2008008241A patent/ECSP088241A/es unknown
-
2015
- 2015-05-13 IL IL238798A patent/IL238798A0/en unknown
- 2015-12-31 HK HK15112923.0A patent/HK1211965A1/xx unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040241174A1 (en) * | 2003-05-14 | 2004-12-02 | Immunogen, Inc. | Drug conjugate composition |
Non-Patent Citations (7)
Title |
---|
CHUN P ET AL: "POTENT ANTI-CANCER ACTIVITY OF DS6-DM1, AN ANTIBODY-DRUG CONJUGATE TARGETING A MUC1 GLYCOTOPE ON OVARIAN, BREAST AND PANCREATIC CARCINOMAS", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 9, no. SUPPL. 16, 1 December 2003 (2003-12-01), pages 6186S,ABSTRACTB205, XP008069628, ISSN: 1078-0432 * |
KEARSE K P ET AL: "MONOCLONAL ANTIBODY DS6 DETECTS A TUMOR-ASSOCIATED SIALOGLYCOTOPE EXPRESSED ON HUMAN SEROUS OVARIAN CARCINOMAS", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, UNITED STATES, SWITZERLAND, GERMANY, vol. 88, no. 88, 1 January 2000 (2000-01-01), pages 866 - 872, XP002907222, ISSN: 0020-7136 * |
MACCALLUM R M ET AL: "Antibody-antigen interactions: Contact analysis and binding site topography", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 262, no. 5, 1 January 1996 (1996-01-01), pages 732 - 745, XP002242391, ISSN: 0022-2836, DOI: 10.1006/JMBI.1996.0548 * |
RUDIKOFF S ET AL: "Single amino acid substitution altering antigen-binding specificity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES (PNAS), NATIONAL ACADEMY OF SCIENCE, US, vol. 79, 1 March 1982 (1982-03-01), pages 1979 - 1983, XP007901436, ISSN: 0027-8424, DOI: 10.1073/PNAS.79.6.1979 * |
See also references of WO2007024222A1 * |
SMITH N L ET AL: "IMMUNOHISTOCHEMICAL DISTRIBUTION OF TUMOR-ASSOCIATED ANTIGEN CA6 IN GYNECOLOGICAL NEOPLASMS AS DETECTED BY MONOCLONAL ANTIBODY DS6", INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, NEW YORK, NY, US, vol. 20, no. 20, 1 July 2001 (2001-07-01), pages 260 - 266, XP002907224, ISSN: 0277-1691 * |
SMITH NL ET AL: "PATTERNS OF EXPRESSION OF THE DS6-GLYCOFORM OF MUC1 CORRELATES WITH KNOWN PROGNOSTIC INDICATORS IN BREAST CANCER", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, vol. 45, 1 January 2004 (2004-01-01), pages 239,ABSTRACT1051, XP001247901, ISSN: 0197-016X * |
Also Published As
Publication number | Publication date |
---|---|
EP1917034A1 (fr) | 2008-05-07 |
ECSP088241A (es) | 2008-04-28 |
CN101242855A (zh) | 2008-08-13 |
WO2007024222A1 (fr) | 2007-03-01 |
BRPI0520509A2 (pt) | 2009-05-12 |
JP2009504193A (ja) | 2009-02-05 |
MX2008002607A (es) | 2008-03-19 |
EA200800642A1 (ru) | 2008-08-29 |
CA2615761A1 (fr) | 2007-03-01 |
EA020130B9 (ru) | 2014-10-30 |
HK1211965A1 (en) | 2016-06-03 |
EA020130B1 (ru) | 2014-08-29 |
NO20080893L (no) | 2008-05-22 |
IL189628A0 (en) | 2008-06-05 |
IL238798A0 (en) | 2015-06-30 |
AU2005335743A1 (en) | 2007-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1211965A1 (en) | A ca6 antigen-specific cytotoxic conjugate and methods of using the same ca6 | |
HK1107672A1 (en) | Conveniently implantable sustained release drug compositions | |
IL191759A0 (en) | Ganaxolone formulations and methods for the making and use thereof | |
ZA200801158B (en) | Sustained drug release composition | |
IL191941A0 (en) | Conjugate vaccines | |
ZAA200500081S (en) | Prosthetic article | |
IL186521A0 (en) | Nanoparticle-active ingredient conjugates | |
EP1912671A4 (fr) | Conjugues lieur a base de beta-glucuronide-medicament | |
AP2006003837A0 (en) | Irinotecan preparation | |
EP2100880A4 (fr) | Dérivé inédit du carbazole et utilisation de celui-ci | |
IL222915A0 (en) | Improved tuberculosis vaccines | |
EP1714643A4 (fr) | Preparation pour liberation soutenue | |
EP1923985A4 (fr) | Actionneur et dispositif holographique l' utilisant | |
EP1802346A4 (fr) | Composition pharmaceutique à libération prolongée | |
EP1718335A4 (fr) | Conjugues de medicaments | |
EP1976490A4 (fr) | Comprimé à libération prolongée contenant du zaltoprofène et procédé de préparation dudit comprimé | |
PL1736119T3 (pl) | Proteza głosu | |
PL1733703T3 (pl) | Proteza głosowa | |
EP2073815A4 (fr) | Promedicaments et conjugues de composes a fonction thiol et selenol, et procedes d'utilisation | |
ZA200800304B (en) | A CA6 antigen-specific cytotoxic conjugate and methods of using the same | |
ZA200805298B (en) | Conjugate vaccines | |
SI1915137T1 (sl) | Pripravek z nadzorovanim sproščanjem za peroralno dajanje | |
EP1946759A4 (fr) | Agent thérapeutique contre la nausée et/ou le vomissement | |
ZA200509261B (en) | Mechanical joint | |
GB0511019D0 (en) | Drug fusions and conjugates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20080125 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK YU |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1111621 Country of ref document: HK |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20090326 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: IMMUNOGEN, INC. |
|
17Q | First examination report despatched |
Effective date: 20090615 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20120110 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1111621 Country of ref document: HK |